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ABSTRACT Shiga toxins (Stx) are the main agent responsible for the development of hemolytic-uremic syndrome (HUS), the most
severe and life-threatening systemic complication of infection with enterohemorrhagic Escherichia coli (EHEC) strains. We pre-
viously described Stx2 expression by eukaryotic cells after they were transfected in vitrowith the stx2 gene cloned into a prokary-
otic plasmid (pStx2). The aim of this study was to evaluate whether mammalian cells were also able to express Stx2 in vivo after
pStx2 injection. Mice were inoculated by hydrodynamics-based transfection (HBT) with pStx2. We studied the survival, percent-
age of polymorphonuclear leukocytes in plasma, plasma urea levels, and histology of the kidneys and the brains of mice. Mice
displayed a lethal dose-related response to pStx2. Stx2 mRNAwas recovered from the liver, and Stx2 cytotoxic activity was ob-
served in plasma of mice injected with pStx2. Stx2 was detected by immunofluorescence in the brains of mice inoculated with
pStx2, andmarkers of central nervous system (CNS) damage were observed, including increased expression of glial fibrillary
acidic protein (GFAP) and fragmentation of NeuN in neurons. Moreover, anti-Stx2B-immunized mice were protected against
pStx2 inoculation. Our results show that Stx2 is expressed in vivo from the wild stx2 gene, reproducing pathogenic damage in-
duced by purified Stx2 or secondary to EHEC infection.
IMPORTANCE Enterohemorrhagic Shiga toxin (Stx)-producing Escherichia coli (EHEC) infections are a serious public health
problem, and Stx is the main pathogenic agent associated with typical hemolytic-uremic syndrome (HUS). In contrast to the de-
tailed information describing the molecular basis for EHEC adherence to epithelial cells, very little is known about how Stx is
released from bacteria in the gut, reaching its target tissues, mainly the kidney and central nervous system (CNS). In order to
develop an efficient treatment for EHEC infections, it is necessary to understand the mechanisms involved in Stx expression. In
this regard, the present study demonstrates that mammals can synthesize biologically active Stx using the natural promoter as-
sociated with the Stx-converting bacteriophage genome. These results could impact the comprehension of EHECHUS, since lo-
cal eukaryotic cells transduced and/or infected by bacteriophage encoding Stx2 could be an alternative source of Stx production.
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Shiga-toxin-producing Escherichia coli (STEC) strains areemergent food-borne pathogens that can cause a range of clin-
ical disease from uncomplicated diarrhea to hemorrhagic colitis
and life-threatening complications, such as hemolytic-uremic
syndrome (HUS) (1–4). The cardinal element of virulence of
STEC/enterohemorrhagic E. coli (EHEC) is the production of
Shiga toxins (Stx), which constitute an AB5 toxin (5). The genes
encoding the two subunits of Stx are located in the genomes of
lambdoid bacteriophages (6), which are efficient vectors for the
transfer of stx and play an important role in the evolution of new
pathogens (7–9). Stx phages can be induced from the lysogenic
strain (10). As a result of prophage induction, bacterial host cells
lyse and release free phage particles that can infect other bacteria
(11–14). However, low levels of spontaneous phage induction can
also occur. It has been demonstrated that most Stx2 prophages are
spontaneously induced more readily than lambdoid prophages
which do not encode Stx (15).
The fate of EHEC infections depends on the interplay between
bacteria and the host, in which the inflammatory response has a
key role. EHEC intestinal infection triggers cytokine synthesis,
particularly of interleukin 8 (IL-8), in the submucosa, which in-
duces recruitment, activation, and migration of neutrophils to the
intestine. In addition, the migration and activation of neutrophils
contribute to the destabilization or epithelial integrity disruption,
increasing Stx absorption and thereby the pathogenicity of EHEC
(16). Furthermore, these neutrophils could also act as carriers of
phage particles.
We previously reported the ability of eukaryotic cells to recog-
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nize wild promoter sequences in the stx2 gene to drive Stx2 expres-
sion by cell lines (17). To analyze whether mammals were capable
of transcribing, translating, and expressing Shiga toxins from the
stx2 gene, we analyzed Stx2 expression in vivo after transfection
with a plasmid construction carrying the stx2 gene under its own
promoter (pStx2). For this purpose, mice were inoculated with
pStx2 by a hydrodynamics-based transfection (HBT) procedure
in which a volume of 8 to 12 ml of a plasmid-containing solution
per 100 g of animal weight was rapidly injected (in less than 8 s)
into the tail vein of mice (18). This gene administration procedure
induces high levels of transgene expression mainly in the liver
(18). For this reason, it has been widely used to evaluate a number
of aspects, including the therapeutic activities of certain genes (19)
and the analysis of regulatory functions of DNA sequences (20),
but also to induce high levels of systemic cytokine expression (21).
In mice with a body weight of 18 to 20 g, an injection volume of
1.6 ml per mouse is almost equivalent to the total blood volume of
the animal (blood volume is estimated to be 7.3% of the body
weight in mice), and then the injected DNA solution is likely to
accumulate in the inferior vena cava when the injection rate ex-
ceeds the cardiac output (18). As a result, a high hydrostatic pres-
sure develops in the inferior vena cava. Such hydrostatic pressure,
being proportional to the volume and the speed of injection,
forces the flow of the DNA solution into tissues such as the liver,
kidney, and heart, which are directly linked to the inferior vena
cava. Since the liver is the largest organ in the body with an ex-
pandable structure, a large portion of the DNA solution is forced
into the liver in a direction that is opposite to that of the regular
circulation. This results in a direct exposure of DNA molecules to
liver cells before they are mixed with the blood.
After the pStx2 HBT procedure, levels of Stx2 mRNA in the
liver and Stx2 biological activity were monitored in the animals.
Mice injected with pStx2 died with typical signs of Stx2 intoxica-
tion, including acute kidney injury, neutrophilia, and central ner-
vous system (CNS) damage. Noticeably, the Stx2 protein was de-
tected in the brain by immunofluorescence, and anti-Stx2B-
immunized mice receiving pStx2 HBT survived and lacked any of
the hallmarks of Stx2 intoxication. These results show that Stx2 is
expressed in vivo after pStx2 HBT, driven by its own wild stx2
promoter. Furthermore, active Stx2 thus produced is able to target
the kidney and the brain and reproduces the lethal damage in-
duced by purified Stx2 or secondary to EHEC infection.
RESULTS
Mice displayed a lethal dose-related response to pStx2. The
hydrodynamics-based transfection (HBT) technique has proven
to be a feasible and efficient way to deliver nonviral hepatic genes
in mice (18, 22). Thus, mice were injected by HBT with different
doses of pStx2 or pStx2AB, a plasmid construction in which the
active site of Stx2 has been deleted (23), or the pGEMT cloning
vector (Promega) without any Stx2 genetic material as an addi-
tional negative control. Mice injected with the highest dose of
pStx2 (3.5 g pStx2/mouse) became agitated and restless within
6 h and died within 24 h. Lower doses of pStx2 showed lethal
effects at later times, as demonstrated by the resulting dose-
response curve (Fig. 1A). HBT produces mainly transfection of
hepatocytes. To evaluate hepatic inflammation, the concentra-
tions of liver-specific enzymes, including alkaline phosphatase
(ALP) and aspartate aminotransferase (AST), were analyzed. All
mice had hepatic enzymes in the normal concentration ranges
(data not shown). Mice inoculated with pStx2AB or pGEMT
survived and showed no signs of toxic effects. These controls al-
lowed us to disregard any damage caused by the plasmid construc-
tion or HBT side effects.
Analysis of gene expression in liver. Because the liver is the
main organ implicated in gene expression after the HBT tech-
nique (18), total RNA was purified from the livers of mice inocu-
lated with pStx2 or pGEMT and analyzed through real-time PCR
using primers of the Stx2 A subunit. In Fig. 1B, the real-time
curves obtained for the negative control (gray; mRNA from livers
of mice inoculated with pGEMT), the positive control (bold; pu-
rified pStx2), and the mRNA from the livers of mice inoculated
FIG 1 (A) Mice displayed a lethal dose-related response to pStx2. Survival rates of mice injected with different doses of pStx2 are shown. Mice injected with
pStx2AB or pGEMT were used as negative controls. Mice injected with 1 LD100 and 3 LD100 of purified Stx2 were used as positive controls. (B) Stx2 mRNA was
detected in the liver. A real-time-PCR curve using cDNA from livers of mice inoculated with pStx2 (dotted line) or pGEMT (gray line) is shown. As a positive
control, 50 pg of plasmid pStx2 (bold line) was used. (C) DNA electrophoresis. Lane 1, 50-bp ladder; lane 2. cDNA from livers of mice inoculated with pStx2; lane
3, cDNA from livers of mice inoculated with pGEMT; lane 4, pStx2 was used as positive control.
Bentancor et al.
2 ® mbio.asm.org September/October 2013 Volume 4 Issue 5 e00501-13
 
m
bio.asm
.org
 o
n
 D
ecem
ber 5, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
with pStx2 (dotted line) are shown. The products of real-time
PCR were loaded on an agarose gel, and the bands observed were
according to the expected size (Fig. 1C).
Evaluation of Stx2 biological activity in plasma.With the aim
of evaluating whether Stx2 expressed in the liver was released into
circulation, plasma from mice inoculated with pStx2, pStx2AB,
or pGEMT was evaluated on Vero cells as the most sensitive test to
detect Stx2 (24). Mice were inoculated with different doses of
pStx2 (3.5 to 0.25 g/mouse) and bled at 24 h, after HBT. We
observed a dose-response effect for Stx2-cytotoxicity (Fig. 2A). To
confirm the specificity in the cytotoxic assay, purified Stx2 equiv-
alent to 1 CD50 (cytotoxic dose that kills 50% of Vero cells)
(4.5 ng/ml) or plasma from mice inoculated with 3.5 g of pStx2
was preincubated with polyclonal anti-Stx2 antibody. Significant
neutralization of the cytotoxicity was observed in both samples
(Fig. 2C). As expected, no cytotoxic effect on Vero cells was ob-
served with plasma from mice inoculated with pGEMT or
pStx2AB.
The amount of Stx2 in plasma was calculated through the Vero
cytotoxic assay using a standard dose-response curve made with
purified Stx2. The toxicity observed in plasma from mice inocu-
lated with 3.5 g of pStx2 was equivalent to that of 172 51 Stx2
ng/ml; the value was 119 7 Stx2 ng/ml for mice inoculated with
0.5 g of pStx2 and 88 13 Stx2 ng/ml for mice inoculated with
0.25 g of pStx2. These results support the high lethal effect of
pStx2 shown in the survival data previously described (Fig. 1A).
Then, we evaluated Stx2 cytotoxicity in plasma at different
time points after inoculation of 3.5 g of pStx2. The kinetic study
showed the maximal Stx2 activity in plasma at 6 h after HBT
(Fig. 2B). As previously reported, the transfection induced by
HBT is transient, and after this time point, the levels of produced
protein slowly decreased.
Laboratory and histological parameters in mice injected
with pStx2. To further characterize the pathogenic effect induced
by pStx2 HBT, mice were inoculated with high or low lethal doses
of pStx2, and biochemical and histopathological changes in the
kidneys and brains of the animals were analyzed. It has been pre-
viously demonstrated using murine models that plasma urea lev-
els are good indicators of acute renal damage during Stx2 intoxi-
cation. Mice injected with 0.25 g of pStx2 died at 72 h after
injection, showing neutrophilia (Fig. 3A), leucopenia, and a sig-
nificant increased in the plasma urea level (Fig. 3B). These results
suggest that mice were able to endogenously produce Stx2, in an
amount and/or timing that led mice to death by acute kidney
injury. In addition, alterations in leukocyte populations were sim-
ilar to those obtained after exogenous injection of purified Stx2 or
oral infection with Stx2-producing E. coli (25, 26). On the other
hand, mice inoculated with 3.5 g or 1 g of plasmid died within
24 h after inoculation with signs of neurological involvement but
no alterations in the laboratory markers related to hepatic or renal
function or leukocyte counts. All mice injected with pStx2AB or
pGEMT remained alive and showed biochemical values similar to
those for nontreated mice.
Histology of kidneys and brains of mice injected with pStx2.
Mice inoculated with pStx2 or pGEMT were histologically stud-
ied. Kidneys from mice inoculated with 0.25 g of pStx2 at 48 h
after HBT showed enlargement of glomeruli due to mesangial
hypercellularity with subsequent obliteration of Bowman’s space.
Tubular epithelia showed features of edema with thickening cyto-
plasmatic alterations and ill-defined luminal edges (Fig. 4B). As
expected, a normal structure of the cortex and medulla was ob-
served in the kidneys of pGEMT-inoculated mice (Fig. 4A). On
the other hand, leukocyte infiltration around necrotic areas was
observed in the brains of mice inoculated with 3.5g of pStx2 and
sacrificed at 24 h after HBT (Fig. 5B). No alterations in the brains
of control mice injected with pGEMT were observed (Fig. 5A).
Immunofluorescence analysis of Stx2 expression inbrains of
mice inoculatedwith pStx2.To elucidate whether the histological
alterations in the brain were the consequence of a direct effect of
Stx2, brains of mice inoculated with pStx2 or pGEMT were eval-
uated by an immunofluorescence assay using a polyclonal anti-
Stx2 antibody (27). As a positive control, we tested mice inocu-
lated with purified Stx2. We observed Stx2-immunopositive cells
in the CA2 hippocampus region of mice inoculated with 3 g of
FIG 2 In vitro evaluation of Stx2 activity in plasma. (A) Vero cells were incubated with plasma from mice inoculated with different doses of pStx2 obtained at
24 h postinoculation. After 48 h of incubation, cells were stained with crystal violet and the optical density at 595 nm (OD595) was measured, as detailed in
Materials and Methods. Each bar represents the mean SEM for 4 mice. *, P 0.03, t test. (B) Kinetic study of Stx2 activity in plasma. Vero cells were incubated
with a 1:60 dilution of plasma from mice inoculated with 3.5g of pStx2 obtained at different times postinoculation. Each time point represents the mean SEM
for 4 mice. (C) In vitro neutralization of Stx2 activity in plasma. Vero cells were incubated with a 1:60 dilution of plasma of mice inoculated with pStx2, pStx2AB
or pGEMT. The specificity of cytotoxicity was evaluated in parallel by preincubating each sample with mouse anti-Stx2 polyclonal antibody (dilution, 1/400) for
1 h at 37°C and for 1 h at 4°C (pStx2 antibodies, pGEMT antibodies, and Stx2 antibodies). As positive and negative controls of cytotoxicity, Vero cells were
incubated with 1 CD50 of Stx2 (Stx2 and Stx2 antibodies) or Vero cells in medium, respectively. After 48 h, cells were stained with crystal violet and the OD595
was measured as detailed in Materials and Methods. Results are means SEM for 4 mice. **, P0.005; ***, P 0.0001.
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pStx2 24 h after HBT (Fig. 6B). Stx2 was also detected in the brains
of mice injected with 0.25g of pStx2 at 48 h after HBT (Fig. 6C).
Control mice inoculated with purified Stx2 (Fig. 6D) showed
numbers of cells immunopositive for Stx2 similar to those of
pStx2 HBT mice (Fig. 6F). The Cortex and hypothalamus also
showed Stx2-positive cells (data not shown).
pStx2 increased expression of GFAP in astrocytes. The hall-
mark of astrocyte (AST) activation is the enhanced expression of
the major intermediate filament protein, glial fibrillary acidic pro-
tein (GFAP) (28). Previously, it has been demonstrated that Stx
increases GFAP expression in AST, both in vitro (29) and in vivo
(30). As depicted in Fig. 7, pStx2 HBT induced the upregulation of
GFAP in the CA2 hippocampus zone at each time point evaluated:
24 h post-3-g dose of pStx2 or 48 h post-0.25-g dose of pStx2.
GFAP has an important role in repairing CNS after injury (31).
We did not observe differences in GFAP expression between the
two different pStx2 doses used (Fig. 7B and C). Vehicle/saline
injection did not induce upregulation of GFAP in comparison
with the treatment.
pStx2 caused neuronal damage, evidenced by NeuN immu-
noreactivity. Since Stx-induced toxicity for neurons has been pre-
viously demonstrated (32, 33), we analyzed neurons by using the
specific neuronal marker NeuN. This marker protein is localized
in the nucleus and the cytoplasm of neurons. Under injury con-
ditions, NeuN in the nucleus becomes immunonegative or frag-
mented but cytoplasmic NeuN keeps stable (34). According to
previous data, while neurons showing intense nuclear reactivity
are considered normal, neurons with NeuN fragmentation in the
FIG 3 Laboratory parameters for mice injected with pStx2. (A) Percentages of polymorphonuclear leukocytes for mice inoculated with 0.25g of pStx2 () or
with 0.25 g pGEMT () at 24 and 48 h after inoculation. Controls versus pStx2, ***, P 0.0004; **, P 0.0037. Each time point represents the mean SEM
for 4 mice. (B) Mice were injected with different doses of pStx2, and plasma urea values were evaluated before death. Each bar represents the mean SEM for
4 mice. ***, P 0.0002.
FIG 4 Kidney histology of cortical zone. (A) Renal glomeruli of a control mouse showed normal structure; lobular organization of the glomeruli and a flat
epithelium lining the glomerular capsule can be seen (arrows). The renal tubules are lined with typical thick cubic epithelium with relatively regular distinct
lumen. H&E stain; magnification,250. (B) Kidney of a mouse inoculated with pStx2 showed glomeruli enlarged with mesangial hypercellularity tightly filling
the Bowmann’s space (arrows). The tubular epithelium showed enlarged cells with ill-defined luminal edges and clumpy cytoplasm. Capillaries are filled with
blood cells; some tubules contain single desquamated cells. H&E; magnification,250.
Bentancor et al.
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nucleus are considered abnormal (34). We observed abnormal
neurons in the brains of mice injected with pStx2 (Fig. 8B and C).
The number of abnormal neurons in mice injected with pStx2 was
significantly higher than that in control mice injected with
pGEMT (Fig. 8G). No significant differences were observed be-
tween pStx2 doses (Fig. 8G).
In vivo neutralization of pStx2 toxicity. We recently reported
that the chimeric protein BLS-Stx2B induces high anti-Stx2B neu-
tralizing antibody titers in mice (35). Then, to confirm that pStx2
toxicity and mortality were dependent on Stx2 production in vivo,
anti-Stx2B-immunized and nonimmunized mice were inoculated
with 0.25 g of pStx2. As shown in Fig. 9A, BLS-Stx2B-
immunized mice showed a significantly higher survival rate (80%)
than nonimmunized control mice (0%). As biochemical parame-
ters that correlate with systemic Stx2 toxicity, the polymorphonu-
clear leukocyte (PMN) percentage and urea level in plasma were
assayed in both groups. All survivors in the immunized group
presented normal plasma urea values (urea g/liter, 36.6 3.6; n
8). Although immunized mice showed an increase in the percent-
age of circulating PMN, it was significantly lower than that in the
nonimmunized mice (Fig. 9B). These results indicate that Stx2
immunized mice were protected against pStx2 toxicity, confirm-
ing that lethal effects of pStx2 are dependent on Stx2.
DISCUSSION
The major finding of this study is the demonstration that mam-
mals are able to express functional Stx2 from the wild stx2 gene
sequence. Furthermore, mice transfected with pStx2 in vivo devel-
oped the main pathogenic signs associated with Stx2 intoxication,
including CNS and renal alterations.
Nowadays there is no doubt about the importance of Stx2 and
Stx2 phage biology to the understanding of HUS. The current
FIG 5 Brain histology. (A) Brain of a control mouse inoculated with pGEMT; no alterations were observed. H&E; magnification,400. (B) Brain of a mouse
inoculated with 0.25 g pStx2 at 24 h after inoculation. Lymphocyte infiltration was observed. H&E; magnification,400.
FIG 6 Localization of Stx2 in brains of mice inoculated with pStx2. The area observed in this study is located in the mouse CA2 hippocampus. (A) Brain from
control mouse inoculated with pGEMT. (B) Brain from mouse inoculated with 3 g of pStx2 24 h after inoculation. (C) Brain from mouse inoculated with
0.25 g of pStx2 48 h after inoculation. (D) Brain from mouse injected with 0.5 ng of Stx2 4 days after injection. (E) Brain from mouse inoculated with 0.25 g
of pStx2 48 h after inoculation, without primary antibody. (F) Number of Stx2-immunopositive cells in hippocampus per micrograph. Scale bar 50 m.
Expression of Stx2 by Mammalian Cells In Vivo
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knowledge states that Stx2 expression is under control of phage
promoters controlled by the phage replication cycle. Therefore,
induction of Stx-converting prophages triggers increased Stx pro-
duction (7, 36, 37). At present, the linkage between the phage
growth cycle and Stx expression is well established on a molecular
level. Besides, following induction, Stx phages can infect other
bacteria present in the gut in vivo and in vitro, and they could also
infect eukaryotic cells, such as epithelial cells, macrophages, or
neutrophils, present in the local inflamed zone. We used a
hydrodynamics-based transfection (HBT) procedure in mice to
test our hypothesis that the gene for Stx2 can be expressed in the
tissues of a mammal, with pathological consequences.
Following this experimental approach, we showed that pStx2
could be efficiently transfected. The RNA analysis of the liver re-
vealed the presence of Stx2-mRNA at 3 h post-pStx2 HBT but not
in mice injected with pGEMT. The totality of previous studies
using HBT to study gene function and regulation, gene therapy,
and DNA vaccination or gene therapy relied on in vivo delivery of
genes under control of eukaryotic promoters, and it is known that
promoter strength is one of the most important parameters deter-
mining the level of gene expression (18, 38). In this regard, among
the many promoters that have been evaluated in mice, cytomega-
lovirus immediate-early promoter (CMV) and human 1-
antitrypsin promoter are generally selected. Both promoters are
similarly effective in expressing genes and also exhibit almost
identical time-response curves. In both cases, the level of gene
expression peaks at 8 h after DNA administration and drops
quickly thereafter.
FIG 7 GFAP expression was increased in astrocytes after pStx2 injection. The area observed in this study is located in the mouse CA2 hippocampus. (A) Brain
from control mouse inoculated with pGEMT. (B) Brain from mouse inoculated with 0.25 g of pStx2 48 h after inoculation. (C) Brain from mouse inoculated
with 3 g of pStx2 24 h after inoculation. (D) Brain from mouse inoculated with 0.25 g of pStx2 48 h after inoculation without primary antibody. Scale bar
25 m. (E) GFAP expression measure by Integral optical density in hippocampus. (F) Colocalization of GFAP and Hoescht 33342 stain. Scale bar 20 m.
FIG8 NeuN immunoreactivity as neuronal damage marker. A significant increase in the number of abnormal nuclei was observed by immunofluorescence with
anti-NeuN antibodies. (A) Brain from control mouse inoculated with pGEMT. (B) Brain from mouse inoculated with 0.25g of pStx2 48 h after inoculation. (C)
Brain from mouse inoculated with 3 g of pStx2 24 h after inoculation. (D) Brain from mouse inoculated with 0.25 g of pStx2 48 h after inoculation with no
primary antibody. Scale bar 50m. (E) Zoomed-in view of picture A. Scale bar 15m. (F) Zoomed-in view of picture C. Scale bar 25m. (G) Numbers
of nuclei with abnormal phenotype.
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In our experimental design, a bacterial gene was translated and
expressed in vivo under its own wild bacterial promoter sequences
by mammalian cells. Although the translation efficiency of pStx2
is probably low, the importance of this finding relies mainly on
two facts. First, this protein has a strong impact in human health.
Infections with STEC/EHEC strains cause HUS, acute renal failure
(1, 4, 39), and less commonly CNS impairment (40). In particular,
it has been reported that the mortality rate from HUS increases
from 0 to 5% to 7 to 40% when the CNS is involved (41–43). This
issue became prominent in Germany in 2011, when the consump-
tion of sprouts containing Stx2 from the unusual enteroaggrega-
tive E. coli O104:H4 resulted in 3,816 cases of gastroenteritis, 845
of which evolved to HUS and 54 to death (44). Second, Stx2 pres-
ents one of the highest biological activities among bacterial toxins.
In fact, concentrations lower than the pg/ml range in mice (ng/
mouse) have been shown to be lethal. It has been recently demon-
strated that a concentration of Stx2 as low as 10 fM is able to
induce ribosome damage and to modulate selected cell signaling
pathways that change cellular functions (45). However, it should
be noted that the Stx2 concentration in blood of HUS patients has
never been determined. Therefore, although the efficiency of pro-
tein synthesis by eukaryotic cells under bacterial promoter se-
quences must be significantly lower than that under the control of
a eukaryotic promoter, the protein concentration systemically
raised was enough to trigger a pathogenic cascade and death in
mice. We were not able to directly detect free Stx2 in the plasma
obtained from mice by Western blotting (WB) after pStx2 HBT.
However, plasma from mice inoculated with pStx2 showed Stx2-
specific cytotoxicity in the Vero cell assay. We observed a peak of
cytotoxicity 6 h after inoculation of mice with 3 g of pStx2. No
cytotoxicity was observed in plasma from control mice injected
with pGEMT or pStx2AB, which had lost the active site of the
toxin. Moreover, in vitro neutralization of plasma cytotoxicity by
anti-Stx2 polyclonal antibodies strongly supports the specificity of
the reaction and the similarity between wild bacterial Stx2 and that
produced in vivo by eukaryotic cells.
Once Stx reaches the tissue, the initial step in the pathogenesis
of STEC HUS is binding of the B subunit to Gb3 on the cell mem-
brane. This step is followed by retrograde transport of the A sub-
unit to the Golgi apparatus and inhibition of protein synthesis in
the ribosome (45). In fact, we not only demonstrated that eukary-
otic cells expressed active and functional Stx2 in vivo but also that
it was able to reproduce all signs and symptoms of Stx2 intoxica-
tion in mice. It is noteworthy that we observed that the death of
the mice was dependent on the dose of pStx2 injected. When pStx2
was injected at a concentration of 0.25 g/mouse, mice died at
72 h with acute renal damage (biochemically and histologically
demonstrated) and with typical neutrophilia (25, 26). These path-
ological signs are similarly observed in mice injected with purified
Stx2 or orally infected with EHEC. In addition, they partially re-
sembled pathological parameters observed in HUS patients. In
particular, the increase in the number of peripheral blood neutro-
phils has been correlated with a poor prognosis (46, 47).
However, mice inoculated with the highest pStx2 dose (3.5g)
died within 24 h post-HBT, with no increase in plasma urea. Be-
cause longer times are necessary to induce lethality secondary to
acute renal damage, death was associated with CNS damage. Sup-
porting this hypothesis, histological brain damage and Stx2 pres-
ence in brains of mice were demonstrated. Those mice showed
CNS injury, evidenced by leukocyte infiltration and activation of
AST, demonstrated by upregulation of GFAP expression. In this
regard, it has been previously reported that intracerebroventricu-
lar administration of Stx2 increases the expression of GFAP, lead-
ing to astrogliosis (30), and that Stx2 causes neuronal death and
glial cell damage in rat brains (33). We also found an increase in
abnormal neuronal nuclei in the brains of mice injected with
pStx2 evaluated by NeuN staining. No data for NeuN and Stx2 are
published, but it is known that normal neurons express a high
signal for NeuN in the nucleus. A decrease in nuclear NeuN ex-
pression was reported for several pathological conditions (48). All
these results led us to conclude that when high doses of pStx2 were
used, mice died of CNS damage as a consequence of direct Stx2
effect. Moreover, we found strong evidence supporting the immu-
nolocalization of Stx2 in the brains of mice. This result would also
FIG 9 In vivo neutralization of Stx2-like biological activity. (A) Offspring from BLS-Stx2B-immunized mice were inoculated with 0.25 g of pStx2 (fill line)
(n 10). Offspring from nonimmunized mice also were inoculated with 0.25 g of pStx2 (broken line) (n 6). Log rank (Mantel-Cox) test, P 0.0229. (B)
Polymorphonuclear leukocyte percentages for mice inoculated with 0.25g of pStx2 after 48 h of inoculation. *,P 0.0231; **,P 0.0024; ***,P 0.0001. Each
bar represents the mean SEM for live mice at 48 h.
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indicate that the Stx2 protein is expressed retaining the quaternary
conformation necessary to bind to its specific receptor, Gb3.
A definitive demonstration that toxicity upon pStx2 HBT was
mediated by Stx2 is that anti-Stx2B-immunized mice were pro-
tected against lethality of pStx2 HBT. In addition, the fact that
high titters of circulating anti-Stx2B antibodies blocked pStx2
HBT toxicity indicates that Stx2 is being expressed in the liver and
probably, after cell death, the toxin is released into systemic circu-
lation to reach its target tissues. In line with this reasoning, Stx2
toxicity was directly detected in the serum from pStx2 HBT mice.
In conclusion, we demonstrated that biologically active Stx2 is
being expressed by mammals cells using the natural promoter
associated with the Stx-converting bacteriophage genome. The
protein thus synthesized by the host retains the natural conforma-
tion that allows it to interact with its target tissues and induces the
typical pathological features associated with bacterial Stx2. These
results could impact STEC HUS comprehension, since local eu-
karyotic cells transduced with and/or infected by bacteriophage
encoding Stx2 could be an alternative source of Stx2 production.
MATERIALS AND METHODS
Plasmid construction. (i) pStx2. The plasmids were constructed by stan-
dard cloning techniques, according to the NIH policy manual on Working
Safely with Hazardous Biological Materials. The complete stx2 sequence
was amplified by PCR from total DNA from E. coli O157:H7 C600
(933W), using the primers Stx2Fw (5= GAATTCATTATGCGTTGTTAG
3=) and Stx2R (5= GAATTCTCAGTCATTATTAAACTG 3=), both con-
taining an EcoRI restriction site (49). The resulting fragment (1,413 bp in
length) was cloned in a pGEMT Easy vector (Promega Inc.), generating
the plasmid pStx2. This plasmid was replicated in E. coli DH5 competent
cells and purified using the Wizard Plus Minipreps DNA purification
system following standardized instructions.
(ii) Control plasmids. The pGEMT Easy vector (Promega Inc.) was
used as a negative control. The pGEMT Easy vector carrying the sequence
of Stx2 was digested and religated in order to delete the active site of Stx2,
generating the plasmid pStx2AB (23) as a Stx2-specific biological activ-
ity control.
In vivo gene expression. Mice were inoculated with 3.5g of pStx2 or
pGEMT using HBT and were sacrificed 3 h after inoculation. Total RNA
was isolated from livers of mice inoculated with pStx2 or pGEMT as a
control. The isolation was made using a single-step phenol/chloroform
extraction procedure (TRIzol; Invitrogen Life Technologies). DNase
treatment was made using RQ1 RNase-free DNase (Promega) following
standardized instructions. cDNA was obtained using Fermentas avian
myeloblastosis virus (AMV) reverse transcriptase (RT).
Real-time PCR was performed on a Smart Cycler real-time machine
(Cepheid, Sunnyvale, CA) using Smart Cycler tubes from Fisher (Sunny-
vale, CA). The reaction was run in the Smart Cycler at an initial 92°C for
120 s and then at 92°C for 10 s and 55°C for 15 s and 72°C for 15 s for 45
cycles using the primers giving a fragment of 147 bp on the stx2 A subunit
(F2A-3, TGGCGTTAATGGAGTTCAGTGG; R2A-3, ACACAGGAGCA
GTTTCAGACAG).
Mice. BALB/c mice were bred in the animal facility of the Institute of
Experimental Medicine, (IMEX), Academia Nacional de Medicina, Bue-
nos Aires. Male mice aged 6 weeks (18 to 20 g) were used throughout the
experiments. They were maintained under a 12-h light-dark cycle at 22
2°C and fed with standard diet and water ad libitum.
HBT of pStx2. The hydrodynamic gene transfer procedure was con-
ducted as described previously (18). In brief, animals were separated into
different groups and injected in the tail vein with different doses of pStx2
(3.5g, 1g, 0.5g, and 0.25g). As controls, we used 3.5g of pGEMT
or 1 g and 0.5 g of pStx2AB. Injections were performed in 1.6 ml of
phosphate-buffered saline (PBS) by hydrodynamic inoculation via the tail
vein. Plasmid injection was completed in less than 8 s.
Hematological studies. Heparinized blood samples were obtained by
puncture of the retroorbital plexus 3 h after pStx2 HBT injection for
laboratory analyses that included total and differential blood cell count in
the Neubauer chamber, blood smears, plasma urea determination, and
liver enzymes. Biochemical determinations of urea and liver enzymes in
plasma were performed using commercial kits (urea color 2R kit and
alkaline phosphatase [ALP] and aspartate aminotransferase [AST] kits;
Wiener Lab, Rosario, Argentina) following standardized instructions
Histological studies. For histological analysis, mice were sacrificed
24 h or 48 h after pStx2 HBT injection (depending of the doses used) and
subjected to necropsy. Mice were transcardially perfused with PBS in or-
der to remove the blood completely, followed by 5% buffer-
formaldehyde. Kidneys and brains were removed, sectioned, fixed in 5%
buffer-formaldehyde, and paraffin embedded. Kidney and brain sections
of paraffin-embedded tissues were stained with hematoxylin and eosin
(H&E) and examined by light microscopy. Tubular injury was evaluated
by assessing the presence of alterations in tubular epithelium, basement
membrane integrity, and necrosis. Vascular interstitial congestion was
also assessed. Another group of mice was sacrificed for immunofluores-
cence. Mice were anesthetized with chloral hydrate (350 mg/kg of body
weight) and perfused transcardially with 0.9% NaCl solution followed by
4% paraformaldehyde in 0.1 M phosphate buffer solution (fixative per
animal weight [ml/g]). Brains were removed from skulls and postfixed in
the same fixative solution for 2 h. Brain sections were cut on a cryostat.
Serial 20-m-thick coronal sections were obtained and collected in 0.1 M
phosphate buffer solution. Brain floating sections obtained were pro-
cessed either for GFAP or NeuN immunofluorescence.
Stx2 preparation. The Stx2 toxin was purified as reported previously
(23). Briefly, E. coli JM109 transformed with plasmid pGEMT-Stx2 was
used to express the Stx2 protein. Supernatants and bacterial lysates were
precipitated with ammonium sulfate at 70% saturation, suspended in
PBS, and dialyzed against the same buffer for 24 h. The total protein
concentration was determined by standard methods. The Stx2 concentra-
tion was determined using a Ridascreen verotoxin kit (R-biopharm AG,
Darmstadt, Germany). The CD50 (cytotoxic dose that kills 50% of Vero
cells) was equivalent to 670 pg of Stx2. One 100% lethal dose (LD100) of
Stx2 is 2.2 ng/mouse, and 3 LD100 is 6.6 ng/mouse.
Anti-Stx2 polyclonal antibodies. BALB/c mice were immunized with
Stx2 toxoid. Stx2 toxoid was prepared by formalin treatment of Stx2 (50).
Briefly, 100 g of Stx2 (Phoenix Lab, Tufts University, Boston, MA) was
incubated overnight in 2% formalin and then dialyzed extensively against
PBS. Mice were immunized biweekly with three injections of 5g of Stx2
toxoid emulsified in Freund’s complete or incomplete adjuvant.
Expression and purification of Stx2-based immunogen. We recently
developed a novel immunogen based on the B subunit of Shiga toxin 2
(Stx2B) and the enzyme lumazine synthase from Brucella spp. (BLS)
(BLS-Stx2B). This chimera was expressed and purified as previously de-
scribed (35). Briefly, inclusion bodies containing BLS-Stx2B were solubi-
lized by overnight incubation in 8 M urea–50 mM Tris-HCl–5 mM
EDTA, pH 8, buffer and dialyzed against 1 M urea–50 mM Tris-HCl–
5 mM EDTA, pH 8.5, buffer. The solubilized proteins were purified by
anion-exchange chromatography in a Q-Sepharose (Pharmacia, GE
Healthcare Life Sciences) column using a high-performance liquid chro-
matography (HPLC) apparatus (Gilson model 320). Elution was per-
formed using a linear gradient between 0 and 1 M NaCl in a 1 M urea–
50 mM Tris-HCl, pH 8.5, buffer. Protein was dialyzed against PBS
previous to each immunization.
BLS-Stx2B immunization protocol. Adult BALB/c female mice were
immunized with 3 doses of BLS-Stx2B, with aluminum hydroxide (sub-
cutaneous), on days 0, 15, and 30. The dose of BLS-Stx2B was equivalent
to 20 g of Stx2B. Females were mated 10 days after the last dose, their
pups were bled every 15 days, and Stx2B-specific antibody titers were
monitored by ELISA. Stx2B-immunized pups were HBT-pStx2 chal-
lenged at 6 weeks postpartum.
Bentancor et al.
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Immunofluorescence of Stx2 and GFAP expression. Immunofluo-
rescence analysis of Stx2 expression localized in the brain was performed
according to a previously published procedure (27). Briefly, brain cryostat
sections (20m) were kept at20° C in cryopreservant solution (50% of
PBS plus 30% ethylene glycol plus 20% glycerol). Sections were incubated
in Triton X-100 (1%) in PBS. Sections were first incubated with 10% of
fetal goat serum in PBS and then were incubated with polyclonal anti-Stx2
antibody (1/50; 1.35 mg/ml) (51) at 4°C for 48 h. Three washes with
Triton X-100 (0.025% in PBS) were done, and then sections were incu-
bated for 1 h with goat IgG anti-rabbit Alexa 555 (1:100) (Sigma, St. Louis,
MO, USA) in PBS. After 3 washes with PBS, sections were mounted on
glass slides and coverslipped in fluorescence mounting solution. Controls
were carried out using the same procedure but omitting the primary anti-
Stx2 antibody.
NeuN, GFAP, and Hoescht stain detection. In parallel, other brain
sections were incubated with polyclonal anti-GFAP polyclonal rabbit
(Z0334; Dako, Glostrup, Denmark) antibody (or anti-NeuN monoclonal
antibody MAB377; Millipore, Temecula, CA, USA) diluted in PBS
(10 mM) plus 0.3% of Triton X-100 (1/500) at 4°C for 4 h at room tem-
perature. Three washes with Triton X-100 (0.025% in PBS) were made,
and then sections were incubated for 90 min with goat IgG anti-mouse
(1:200) (Sigma, St. Louis, MO, USA) in PBS. After 3 washes with PBS,
sections were incubated with Hoescht 33342 stain (1 g/l) for 30 min.
After three washes with PBS, sections were mounted on glass slides and
coverslipped in fluorescence mounting solution. Controls were carried
out using the same procedure but omitting the primary anti-Stx2 anti-
body.
Eight sections per treatment were analyzed, and 16 micrographs per
section were used to take images. Images were captured from a Zeiss
Axiophot microscope (Germany) with the Fluo View application soft-
ware. Serial optical sections were obtained using a Simple 32 C-imaging
computer. Images were taken with a scan zoom of1. Adobe Photoshop
software was used to assemble the images and obtain merged images.
Statistical analysis. The significance of the difference between treat-
ments was analyzed using Prism 5.0 software (GraphPad Software), and
the P value is indicated by asterisks in the figures.
Survival and frequency data were analyzed for significance using the
log rank test and 2 test. All other data correspond to the means stan-
dard errors of the means (SEM) for individual mice. Statistical differences
were determined using the one-way analysis of variance (ANOVA). Com-
parisons a posteriori between two groups were performed using Student-
Newman-Keuls analysis.
Ethics statement. Experiments performed herein were approved by
the local Institutional Animal Care and Use Committee of Instituto de
Medicina Experimental (IMEX), in accordance with the principles set
forth in the Guide for the Care and Use of Laboratory Animals (National
Institutes of Health, 1985).
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